Today: 21 March 2026
Subscribe
Browse Category

NASDAQ:MFH 3 October 2025 - 6 October 2025

Mercurity Fintech (MFH) Stock Explodes Amid Crypto & AI Bets – 1,000% Rally or Bubble?

Mercurity Fintech (MFH) Stock Skyrockets 1,400% in Crypto & AI Boom – Next Fintech Breakout or Bubble?

Mercurity Fintech Holding Inc. (NASDAQ: MFH) stock surged over 1,300% year-to-date in 2025, reaching an all-time high near $30 and a market cap close to $1.3 billion. The New York-based blockchain fintech shifted strategy to invest up to $500 million in crypto assets, backed by a $200 million Solana Ventures credit line. MFH joined the Russell 2000 and S&P Global indices this year. Full-year 2024 revenue was $1.01 million, with a $4.5 million net loss.
6 October 2025
···
Mercurity Fintech (MFH) Stock Explodes Amid Crypto & AI Bets – 1,000% Rally or Bubble?

Up 1,400% in a Year: Is Mercurity Fintech (MFH) the Next Crypto-Fintech Breakout or a Bubble?

Mercurity Fintech Holding (NASDAQ: MFH) stock has soared over 1,400% in the past year, reaching an all-time high near $30. The company pivoted to a $500 million crypto treasury strategy focused on Solana, securing a $200 million credit line from Solana Ventures after shelving a planned $43.7 million offering. MFH joined the Russell 2000 and S&P Global BMI in 2025. Despite this, 2024 revenue was just $1.01 million, with a $4.5 million net loss.
4 October 2025
····
Mercurity Fintech (MFH) Stock Explodes Amid Crypto & AI Bets – 1,000% Rally or Bubble?

Mercurity Fintech (MFH) Stock Explodes Amid Crypto & AI Bets – 1,000% Rally or Bubble?

Mercurity Fintech (NASDAQ: MFH) surged about 1,320% year-to-date, trading near $28 on Oct 3, 2025, after starting 2024 near $1. The stock saw sharp swings, including a 27.6% drop Oct 1 and a 15.8% gain Oct 2. Recent moves include a $200M Solana venture line, gold asset tokenization deals, and index additions. Analyst consensus remains bearish, with a “Hold” rating and $4 price target.
3 October 2025
···

Stock Market Today

  • Grail Shares Surge 12.4% After Analyst Upgrade Amid Trial Uncertainty
    March 21, 2026, 6:53 AM EDT. Shares of multi-cancer early detection company Grail jumped up to 12.4% this week following a Wall Street analyst's rating upgrade from "hold" to "buy." The new price target, however, was lowered to $65, still offering a 39% premium over the last close. This comes despite the company missing its primary endpoint in a key trial measuring stage III-IV cancer detection reductions with its Galleri test. The trial did show promising increases in early-stage cancer detection and reduced late-stage cases, which investors hope will be bolstered by upcoming follow-up data. Analyst TD Cowen cited potential for FDA approval and insurance coverage as reasons for optimism in a volatile healthcare stock environment.
Go toTop